Flagship Pioneering Launches Sigilon Therapeutics to Advance Afibromer™ Encapsulated Cell Therapies

– Category-defining platform to engineer biocompatible encapsulated cell therapeutics to treat serious diseases 
– Company assembles leadership team with extensive success in cell biology, translational materials science, medical research and biopharmaceutical development 

Cambridge, Mass. (June 21, 2017) – Flagship Pioneering, a fully-integrated life science innovation enterprise, announced the launch of Sigilon Therapeutics Inc. Sigilon Therapeutics is a biopharmaceutical company that discovers and develops category-defining biocompatible encapsulated cell therapies. Sigilon Therapeutics’ discovery platform combines cell engineering and revolutionary biocompatible Afibromer^™ technology, a new class of implantable biomaterials that do not trigger fibrosis. [Read more…]